Ahpra registration PHY0002298174
How these guides are written and reviewed →
Some lung diseases are caused by breathing in harmful dusts at work — such as silica, asbestos, coal or certain organic dusts — over months or years. The fine particles scar or inflame the lungs, causing breathlessness and cough that may appear long after the exposure. Diagnosis relies on knowing your work history alongside scans and breathing tests, and the most important step is preventing further exposure. Management supports the lungs and treats symptoms, and some conditions are compensable. This page explains dust-related lung diseases and how they are managed.
Pneumoconiosis refers to a group of interstitial lung diseases caused by inhalation of mineral or organic dusts in the workplace. In Australia, silicosis (particularly from engineered stone), coal worker’s pneumoconiosis, and asbestos-related disease are the dominant entities. The resurgence of artificial stone silicosis in young workers led the Commonwealth and States to prohibit the manufacture, supply and installation of engineered stone benchtops from 1 July 2024.
Definition
Pneumoconioses are chronic interstitial lung diseases caused by deposition and retention of inhaled inorganic dust, with a pathological reaction that may be fibrotic (silicosis, asbestosis, coal worker’s pneumoconiosis), granulomatous (chronic beryllium disease), or both. Hard metal lung disease, talcosis, and welder’s lung complete the group of occupationally relevant disorders.1
Pathophysiology
Inhaled particles smaller than 5 micrometres reach the respiratory bronchioles and alveoli, where they are phagocytosed by alveolar macrophages. Macrophage activation, release of cytokines and reactive oxygen species, and recurrent injury–repair cycles produce nodular or diffuse fibrosis. Silica, in particular, is a potent activator of the NLRP3 inflammasome.
Disease pattern is determined by the type of dust, particle size and respirability, cumulative exposure, exposure intensity, and host factors. Higher-intensity exposures (such as dry-cutting engineered stone) can cause accelerated and acute silicosis within months rather than the classic decades-long latency.
Major Australian entities
Silicosis (chronic, accelerated, and acute) — increasingly from engineered (artificial) stone benchtop fabrication, also tunnelling, sandblasting, mining, foundry work, and stone masonry.
Coal worker’s pneumoconiosis (CWP) and progressive massive fibrosis — resurgent in Queensland coal miners since 2015.
Asbestosis and asbestos-related pleural disease — legacy exposure in construction, shipbuilding, mining (Wittenoom), and home renovation.
Mixed-dust pneumoconiosis, hard metal lung disease, chronic beryllium disease, welder’s lung, and silo-filler’s disease are less common but reportable.2,3,4
Causes and at-risk occupations
Engineered stone fabrication, stone masonry and tile cutting, sandblasting, foundry work, ceramic and glass manufacture, tunnelling, hard rock mining (gold, silver, coal), construction (concrete cutting, demolition), shipbuilding and ship repair, asbestos product manufacture, brake and clutch repair, agricultural work (organic dust), and welding.
Central Queensland, with its coal mining, construction, agricultural and rail engineering base, has a higher background prevalence of occupational lung disease than the national average.5,6
Symptoms
Insidious progressive dyspnoea, dry cough, fatigue, chest tightness, and reduced exercise tolerance. Acute and accelerated silicosis can present with rapid symptom onset, fever, and weight loss. Asbestos-related pleural disease is often asymptomatic until effusion or mesothelioma develops.
Associated and complicating conditions
Silica exposure increases the risk of tuberculosis, non-tuberculous mycobacterial infection, autoimmune disease (systemic sclerosis, rheumatoid arthritis, lupus), chronic kidney disease, COPD, and lung cancer. Asbestos exposure increases the risk of lung cancer (synergistic with smoking), mesothelioma, and laryngeal and ovarian cancer.
Diagnosis
Why diagnosis matters
Diagnosis is essential for removal from ongoing exposure, eligibility for workers’ compensation and statutory schemes, surveillance for complications (lung cancer, mesothelioma, autoimmune disease), and access to specialist follow-up. In Queensland, coal and metalliferous mine workers have a statutory health surveillance scheme with its own referral pathway — see Mine Dust Lung Disease Screening. In Australia, all suspected and confirmed cases of silicosis are notifiable in most jurisdictions.
Occupational history
A detailed lifetime occupational and exposure history is the foundation of diagnosis — every job, dust exposure, use of respiratory protective equipment, and exposure intensity should be documented. Hobbies (home renovation, sandblasting, ceramics) and military service should also be covered.
Radiology
High-resolution CT chest is the imaging modality of choice and is more sensitive than chest radiography. The International Labour Organization (ILO) classification is used to grade radiographic abnormalities for medico-legal purposes.
Silicosis: upper-zone predominant centrilobular nodules, hilar lymphadenopathy with eggshell calcification, and progressive massive fibrosis in advanced disease. Asbestosis: lower-zone reticulation with subpleural distribution, often with pleural plaques and pleural thickening. CWP: upper-zone nodules with progression to PMF.
Lung function
A restrictive pattern with reduced DLCO is typical of established fibrotic disease. Mixed patterns occur with co-existing smoking-related airways disease. Serial spirometry is the cornerstone of surveillance.7
Other investigations
Autoantibody screening (silica is associated with autoimmunity), tuberculosis screening, and where indicated transbronchial lung biopsy or surgical lung biopsy. Beryllium lymphocyte proliferation testing is required for suspected chronic beryllium disease.8
Management
Removal from exposure
The single most important intervention is identification and complete removal of the worker from further dust exposure. Continued exposure is associated with disease progression regardless of other treatments. Reporting to the relevant State workplace health and safety authority is required for notifiable diseases.9
Australian surveillance and compensation
Queensland operates the Coal Mine Workers’ Health Scheme for current and former coal mine workers. The National Occupational Respiratory Disease Registry, established by Safe Work Australia, has commenced national data collection for silicosis and other occupational lung diseases.
Workers should be supported to access workers’ compensation (state-based) and, where applicable, the Asbestos Injuries Compensation Fund and state asbestos victims’ schemes. Veterans should be referred to DVA pathways.10
Disease-specific treatment
No proven disease-modifying pharmacotherapy exists for established pneumoconiosis. Treatment focuses on managing symptoms, complications and co-morbidities — bronchodilators for co-existing airflow obstruction, oxygen for hypoxaemia, immunosuppression for autoimmune complications, and tuberculosis treatment when reactivation occurs.
Vaccination, infection prevention and lung cancer surveillance
Annual influenza, COVID-19 boosters, pneumococcal and pertussis vaccination. Eligibility for the National Lung Cancer Screening Program (commenced 1 July 2025) should be reviewed in all current and former smokers with occupational dust exposure. Asbestos-exposed individuals warrant a discussion of mesothelioma awareness and clinical surveillance pathways.
Lung transplantation
Lung transplantation is offered in selected younger patients with end-stage silicosis or asbestosis and no contraindications. The young age of patients presenting with accelerated artificial stone silicosis has increased demand for transplant assessment in this population.
Medications
Symptom and complication management
Bronchodilators for co-existing airflow obstruction, inhaled corticosteroids if indicated by phenotype, supplemental oxygen for hypoxaemia, anti-fibrotic agents (pirfenidone, nintedanib) considered off-licence in some progressive fibrotic phenotypes following MDT discussion.
Multi-system manifestations
Autoimmune disease
Silica exposure is associated with systemic sclerosis (the Erasmus syndrome), rheumatoid arthritis (Caplan syndrome with concomitant CWP), systemic lupus erythematosus, and ANCA-associated vasculitis. Persistent musculoskeletal, dermatological, or renal symptoms warrant investigation.
Tuberculosis and other infections
Silica impairs macrophage function and increases the risk of tuberculosis (silico-tuberculosis), non-tuberculous mycobacterial infection, and fungal infection. Tuberculosis screening at diagnosis is recommended.
Cardiovascular and renal disease
Silica exposure is independently associated with cardiovascular mortality and chronic kidney disease. Routine cardiovascular risk-factor assessment and renal function monitoring are appropriate.
Malignancy
Silica is a Group 1 carcinogen (lung cancer). Asbestos is a Group 1 carcinogen (lung cancer, mesothelioma, ovarian, laryngeal). Surveillance pathways differ; both populations benefit from National Lung Cancer Screening Program participation where eligible.
Living with occupational lung disease
Pulmonary rehabilitation
Pulmonary rehabilitation improves exercise capacity, dyspnoea, and quality of life in occupational lung disease. Programmes should account for psychological impact (loss of livelihood, anger, fear of progression) and may benefit from joint delivery with peer-support and legal-aid pathways.
Smoking cessation
The interaction between cigarette smoking and dust exposure is multiplicative for both lung cancer (especially asbestos) and progression of airflow obstruction. Smoking cessation support should be offered systematically.
Psychological and financial impact
A diagnosis of occupational lung disease often involves grief, anger, financial hardship, and ongoing legal processes. Early referral to social work, peer support (the Australian Workers’ Union and dust disease support groups), and financial counselling is valuable.
Family screening and prevention
Co-workers, especially those who worked alongside the index case in dry-cutting or high-exposure roles, should be encouraged to access workplace medical surveillance. Take-home asbestos and silica exposures to family members have been described and should be considered.
Travel and prognosis
Prognosis depends on disease type, severity at diagnosis, exposure cessation and complications. Acute and accelerated silicosis carry a particularly poor prognosis and warrant prompt referral for transplant assessment in eligible patients.
Role of the physiotherapist
The physiotherapist delivers pulmonary rehabilitation and exercise to maintain capacity, teaches breathing and pacing strategies for breathlessness, provides airway clearance where sputum is a feature, and supports education around exposure avoidance and self-management.
Warning signs
Part 1 · References
- Blanc PD, Annesi-Maesano I, Balmes JR, et al. The occupational burden of nonmalignant respiratory diseases: an official American Thoracic Society and European Respiratory Society statement. Am J Respir Crit Care Med 2019;199(11):1312–1334.
- Leung CC, Yu ITS, Chen W. Silicosis. Lancet 2012;379(9830):2008–2018.
- Zosky GR, Hoy RF, Silverstone EJ, et al. Coal workers' pneumoconiosis: an Australian perspective. Med J Aust 2016;204(11):414–418.
- Australian Institute of Health and Welfare. Mesothelioma in Australia 2023. Canberra: AIHW; 2024.
- Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management of work-related asthma: American College of Chest Physicians consensus statement. Chest 2008;134(3 Suppl):1S–41S.
- Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of hypersensitivity pneumonitis in adults: an official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2020;202(3):e36–e69.
- Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update: an official ATS and ERS technical statement. Am J Respir Crit Care Med 2019;200(8):e70–e88.
- Hoy RF, Glass DC, Dimitriadis C, Hansen J, Hore-Lacy F, Sim MR. Identification of early-stage silicosis through health screening of stone benchtop industry workers in Victoria, Australia. Occup Environ Med 2021;78(4):296–302.
- Vandenplas O, Dressel H, Wilken D, et al. Management of occupational asthma: cessation or reduction of exposure? A systematic review of available evidence. Eur Respir J 2011;38(4):804–811.
- Safe Work Australia. Prohibition on the use of engineered stone: model WHS regulations. Canberra: Safe Work Australia; 2024.
References are numbered in citation order (Vancouver/BMJ style) and were current at the time of writing. Guidelines are living documents — verify against the latest version before clinical use.
More than one of our services applies here, and which combination suits you depends on what your assessment shows.
Clinical evidence
Part 1 covers the same condition without the technical detail. What follows is the evidence base behind it, written for clinicians — the literature, the reasoning and the gaps.
For clinicians: this summary supports clinical reasoning and is not a protocol. Check current guidelines and local policy before applying it, and read it alongside the key references and guidelines directory.
Framing. Occupational lung disease is the one respiratory category where the most effective treatment is administrative: identifying and ending the exposure. It also carries a much larger share of common disease than is generally assumed — the ATS/ERS statement attributes a substantial population fraction of COPD, asthma and interstitial disease to workplace exposures.1 Australia has had two contemporary epidemics to prove the point: artificial-stone silicosis in benchtop workers, which led to a national prohibition on the use of engineered stone from July 2024, and re-emergent coal workers' pneumoconiosis in Queensland.2,3,4
Disease groups and what changes outcome
- Artificial-stone silicosis presents younger, progresses faster and includes accelerated and complicated forms with high rates of progressive massive fibrosis; there is no disease-modifying therapy, so exposure cessation, surveillance and transplant referral carry the load.2,5
- Occupational asthma: outcomes depend on early diagnosis and complete removal from exposure — continued exposure, even at reduced levels, is associated with worse long-term lung function than removal.6,7
- Hypersensitivity pneumonitis from occupational organic antigens requires the same rigorous exposure history; removal is the single most effective intervention and can halt progression.8
- Asbestos-related disease (pleural plaques, diffuse pleural thickening, asbestosis, mesothelioma, lung cancer) has a decades-long latency, meaning current presentations reflect historical exposure and attract compensation pathways.9
- Health surveillance with spirometry and imaging is the mechanism by which these diseases are found early enough to matter, and interpretation requires correct technique and reference equations.10
Rehabilitation evidence
- Pulmonary rehabilitation improves exercise capacity, dyspnoea and quality of life in fibrotic and obstructive occupational disease by extension from the ILD and COPD evidence base — there are no dust-disease-specific trials.5,8
- Airway clearance has no routine role in pneumoconiosis or fibrotic occupational disease; it is indicated only where a coexisting suppurative or obstructive process produces genuine sputum retention.
- Breathlessness management, pacing and anxiety strategies are the highest-yield interventions in advanced dust disease, as in other progressive fibrotic conditions.5
Physiotherapy implications
- Take a full occupational history on every respiratory patient — every job, exposures, duration, protective equipment, second jobs and hobbies. It changes diagnosis, compensation and, critically, whether other workers are still being exposed.1
- Ask the pattern-recognition questions for occupational asthma: symptoms better on days off and holidays, worse within hours of specific tasks, and improving on leave. A positive pattern warrants urgent referral for objective testing before the job is left.6,7
- Do not advise a patient to resign or to keep working — both have major financial and medico-legal consequences. Refer to an occupational or respiratory physician and document what you observed.
- Report and refer: silicosis and other dust diseases are notifiable in Australian jurisdictions, and compensation and dust-diseases schemes exist; physiotherapy documentation of functional loss supports claims.3,9
- Prescribe for a desaturating fibrotic patient where relevant: interval training, oximetry, supplemental oxygen if prescribed, resistance work for steroid-related and disuse weakness.5
- Reinforce exposure control where work continues: fit-tested respiratory protection, wet cutting and local exhaust ventilation, and no dry cutting — while being clear that engineering controls, not masks, are the primary defence.2
- Escalate rapid symptomatic progression, new resting hypoxaemia, haemoptysis, or weight loss — and remember the raised risks of tuberculosis and lung cancer in silica-exposed workers.5
Clinical reasoning
- A young worker with breathlessness and abnormal imaging is a dust-disease question until proven otherwise — the classic diagnostic delay comes from assuming youth excludes fibrosis.2
- Symptoms that track the working week are the strongest clue to occupational asthma and are easy to elicit and easy to miss.6
- One diagnosed worker implies a workplace, not an individual, so the question "who else works there?" belongs in the referral letter.
- Distinguish progressive fibrotic disease (plan for decline, refer for transplant assessment early) from removable exposure disease (expect stabilisation or improvement).
Evidence gaps
- No rehabilitation trials exist in silicosis or coal workers' pneumoconiosis; practice is extrapolated entirely from IPF and COPD populations.5
- Progression rates, and predictors of progression, in artificial-stone silicosis are still being characterised in cohorts.2
- The optimal surveillance interval and imaging modality after exposure ceases are unresolved.10
- Whether any intervention modifies the course of established pneumoconiosis remains unknown.
For Queensland coal and metalliferous mine workers, the statutory surveillance scheme sets the screening interval, the spirometry standard and the escalation pathway — see Mine Dust Lung Disease — Clinical Pathways.
References for the clinical evidence summary
- Blanc PD, Annesi-Maesano I, Balmes JR, et al. The occupational burden of nonmalignant respiratory diseases: an official American Thoracic Society and European Respiratory Society statement. Am J Respir Crit Care Med 2019;199(11):1312–1334.
- Hoy RF, Glass DC, Dimitriadis C, Hansen J, Hore-Lacy F, Sim MR. Identification of early-stage silicosis through health screening of stone benchtop industry workers in Victoria, Australia. Occup Environ Med 2021;78(4):296–302.
- Safe Work Australia. Prohibition on the use of engineered stone: model WHS regulations. Canberra: Safe Work Australia; 2024.
- Zosky GR, Hoy RF, Silverstone EJ, et al. Coal workers' pneumoconiosis: an Australian perspective. Med J Aust 2016;204(11):414–418.
- Leung CC, Yu ITS, Chen W. Silicosis. Lancet 2012;379(9830):2008–2018.
- Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management of work-related asthma: American College of Chest Physicians consensus statement. Chest 2008;134(3 Suppl):1S–41S.
- Vandenplas O, Dressel H, Wilken D, et al. Management of occupational asthma: cessation or reduction of exposure? A systematic review of available evidence. Eur Respir J 2011;38(4):804–811.
- Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of hypersensitivity pneumonitis in adults: an official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2020;202(3):e36–e69.
- Australian Institute of Health and Welfare. Mesothelioma in Australia 2023. Canberra: AIHW; 2024.
- Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update: an official ATS and ERS technical statement. Am J Respir Crit Care Med 2019;200(8):e70–e88.
Corrections: If something on this page is wrong, out of date or unclear, we want to know. Email reception@inspireclinic.au with the page name and what you believe is incorrect. Substantive corrections are made promptly, and the guide’s version and last-updated date are changed to reflect it.